FindTrial
Sign In

GB1211

DRUG6 trials

Sponsors

Galecto Biotech AB, Providence Health & Services

Conditions

Head and Neck Squamous Cell CarcinomaHepatic ImpairmentMetastatic MelanomaNon-Small Cell Lung CancerNon-alcoholic Steatohepatitis (NASH)PharmacokineticsSafety and Tolerability

Phase 1

A First in Human Study to Evaluate the Safety, Tolerability and PK of GB1211 in Healthy Subjects
CompletedNCT03809052
Galecto Biotech ABSafety and Tolerability
Start: 2019-01-14End: 2019-06-25Updated: 2021-03-17
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Orally Administered GB1211 in Participants With Suspected or Confirmed Non-alcoholic Steatohepatitis (NASH) and Liver Fibrosis
WithdrawnNCT04607655
Galecto Biotech ABNon-alcoholic Steatohepatitis (NASH)
Start: 2021-03-31End: 2022-07-31Updated: 2021-02-04
A Single and Repeat Dose Trial in Participants With Hepatic Impairment
NCT05009680
Galecto Biotech ABHepatic Impairment
Start: 2021-09-09End: 2023-07-04Target: 54Updated: 2023-05-11
A Study to Investigate the Safety and Efficacy of GB1211 (a Galectin-3 Inhibitor) in Combination With Atezolizumab in Patients With Non-Small Cell Lung Cancer (NSCLC).
Active, not recruitingNCT05240131
Galecto Biotech ABNon-Small Cell Lung Cancer
Start: 2022-03-15End: 2025-11-01Target: 88Updated: 2024-04-12
A Study to Compare Pharmacokinetics of GB1211
CompletedNCT05747573
Galecto Biotech ABPharmacokinetics
Start: 2023-01-03End: 2023-04-10Updated: 2023-09-01

Phase 2

GB1211 and Pembrolizumab Versus Pembrolizumab and Placebo in Patients With Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma
Active, not recruitingNCT05913388
Providence Health & ServicesHead and Neck Squamous Cell Carcinoma, Metastatic Melanoma
Start: 2024-02-29End: 2030-02-01Updated: 2026-09-16

Related Papers

Single‑Dose Pharmacokinetics and Safety of the Oral Galectin‑3 Inhibitor, Selvigaltin (GB1211), in Participants with Hepatic Impairment.
2024-10-024 citations
Relative bioavailability and food effect of the galectin-3 inhibitor selvigaltin (GB1211) administered as a tablet in healthy participants (GALBA-1).
2024-08-211 citations
Safety and pharmacokinetics of GB1211, an oral galectin-3 inhibitor: a single- and multiple-dose first-in-human study in healthy participants
Cancer Chemotherapy and Pharmacology2023-03-0136 citations
GALLANT-1: Galectin-3 (Gal-3) inhibitor GB1211 plus atezolizumab (atezo) in patients with non–small cell lung cancer (NSCLC)—A randomized, double-blind trial.
Journal of Clinical Oncology2022-06-014 citations